Literature DB >> 21269851

Orexin/hypocretin plays a role in the response to physiological disequilibrium.

Christopher M Sinton1.   

Abstract

In the decade since the discovery that pathology of the orexin/hypocretin system is causative for the sleep disorder narcolepsy, considerable progress has been made in understanding the functional role of the neuropeptide. Two, apparently separate functions of orexin have emerged as a consensus from studies to date. The first is the effect on vigilance state boundaries, as exemplified by narcolepsy. Thus the absence of orexin severely limits the ability to maintain prolonged periods of wakefulness or sleep and also allows the unregulated appearance of cataplexy as sudden muscle weakness during wakefulness. The second function is that orexin acts as a signaling molecule in transferring information about physiological disequilibrium to the central nervous system. Orexin activates the central arousal and motor systems during such disequilibrium and so may facilitate the necessary response and adaptation to restore equilibrium. A feasible relationship between these two functions is therefore that the maintenance of prolonged and active wakefulness is an integral part of this adaptive process. Furthermore, the limit placed on the onset of sleep by orexin suggests that these adaptive processes then continue during sleep to become integrated into the development of a coping strategy for the longer term.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269851     DOI: 10.1016/j.smrv.2010.12.003

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  12 in total

1.  Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.

Authors:  Vijayakumar Mavanji; Claudio E Perez-Leighton; Catherine M Kotz; Charles J Billington; Sairam Parthasarathy; Christopher M Sinton; Jennifer A Teske
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 2.  REM sleep: a biological and psychological paradox.

Authors:  Jerome M Siegel
Journal:  Sleep Med Rev       Date:  2011-04-08       Impact factor: 11.609

3.  Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level.

Authors:  Ronald McGregor; Ming-Fung Wu; Grace Barber; Lalini Ramanathan; Jerome M Siegel
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

4.  CSF levels of hypocretin-1 (orexin-A) peak during early infancy in humans.

Authors:  Adi Aran; Irina Shors; Ling Lin; Emmanuel Mignot; Michael S Schimmel
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

5.  GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

6.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

7.  Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis.

Authors:  Clifford S Deutschman; Nichelle R Raj; Erin O McGuire; Max B Kelz
Journal:  Crit Care Med       Date:  2013-11       Impact factor: 7.598

Review 8.  Narcolepsy: neural mechanisms of sleepiness and cataplexy.

Authors:  Christian R Burgess; Thomas E Scammell
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

9.  Early expression of hypocretin/orexin in the chick embryo brain.

Authors:  Kyle E Godden; Jeremy P Landry; Natalya Slepneva; Paola V Migues; Maria Pompeiano
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

10.  LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.

Authors:  Thomas E Fitch; Mark J Benvenga; Cynthia D Jesudason; Charity Zink; Amy B Vandergriff; Michelle M Menezes; Douglas A Schober; Linda M Rorick-Kehn
Journal:  Front Neurosci       Date:  2014-01-28       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.